BMRN — BioMarin Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $10.85bn
- $14.16bn
- $3.22bn
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife
U.S. STOCKS ON THE MOVE-Kaiser Aluminum, EPAM Systems, software stocks
U.S. STOCKS ON THE MOVE-Science Applications, GameStop, Aon PLC
U.S. STOCKS ON THE MOVE-Pinterest, Intel, SLB
BioMarin climbs on global patent settlement with Ascendis
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals
U.S. STOCKS ON THE MOVE-BioMarin Pharmaceutical, Home Depot, Klarna Group
BioMarin up after agreeing to buy drug developer in deal worth up to $490 million
Brief: Biomarin To Acquire Alesta Therapeutics To Gain Ale1, A Potential First Oral Therapy For Hypophosphatasia
U.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
BioMarin Pharmaceutical Inc. reports results for the quarter ended June 30 - Earnings Summary
BioMarin Q2 revenue beats estimates; raises 2026 outlook
Brief: Biomarin Pharmaceutical Q2 EPS USD 0.23
BioMarin Pharmaceutical Inc expected to post earnings of 69 cents a share - Earnings Preview
Brief: Biomarin Pharmaceutical - And N-Lorem Announce Global Exclusive License To Develop Aso Medicine For Renu Syndrome
U.S. STOCKS ON THE MOVE-Moderna, Kontoor Brands, Ralph Lauren